Health Care [ 8/12 ] | Biotechnology [ 38/75 ]
NASDAQ | Common Stock
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer.
The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.
It also develops PIVOT-006, a cretostimogene monotherapy that is in phase 3 clinical trial for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008, which is in phase 2 clinical trial for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients.
The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020.
CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 14, 25 | -0.57 Decreased by -90.00% | -0.55 Decreased by -4.26% |
| Aug 8, 25 | -0.54 Decreased by -92.86% | -0.44 Decreased by -22.12% |
| May 13, 25 | -0.45 Decreased by -25.00% | -0.37 Decreased by -20.32% |
| Mar 28, 25 | -0.46 Decreased by -39.01% | -0.45 Decreased by -2.22% |
| Nov 12, 24 | -0.30 | -0.42 Increased by +28.57% |
| Aug 8, 24 | -0.28 | -0.40 Increased by +30.00% |
| May 9, 24 | -0.36 | -0.29 Decreased by -24.14% |
| Mar 26, 24 | -0.33 | -0.67 Increased by +50.61% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 1.67 M Increased by +3.77 K% | -43.81 M Decreased by -114.69% | Decreased by -2.63 K% Increased by +94.46% |
| Jun 30, 25 | 0.00 Decreased by -100.00% | -41.43 M Decreased by -119.16% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 52.00 K Decreased by -90.17% | -34.45 M Decreased by -103.47% | Decreased by -66.25 K% Decreased by -1.97 K% |
| Dec 31, 24 | 456.00 K Increased by +45.50 K% | -31.80 M Decreased by -97.31% | Decreased by -6.97 K% Increased by +99.57% |
| Sep 30, 24 | 43.00 K Increased by +377.78% | -20.41 M Decreased by -73.39% | Decreased by -47.45 K% Increased by +63.71% |
| Jun 30, 24 | 111.00 K Increased by +N/A% | -18.90 M Decreased by -62.77% | Decreased by -17.03 K% Decreased by N/A% |
| Mar 31, 24 | 529.00 K Increased by +172.68% | -16.93 M Decreased by -95.36% | Decreased by -3.20 K% Increased by +28.36% |
| Dec 31, 23 | 1.00 K Increased by +N/A% | -16.12 M Decreased by -92.04% | Decreased by -1.61 M% Decreased by N/A% |